127P Phase I study of fianlimab: A human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced NSCLC
| Autor: | Cho, B.C., Dy, G., Kim, T.M., Sarker, D., Hamid, O., Williamson, S., Sang-We, K., Hatim, H., Chen, S., Mani, J., Jankovic, V., Paccaly, A.J., Masinde, S., Lowy, I., Brennan, L., Gullo, G. |
|---|---|
| Zdroj: | In Immuno-Oncology and Technology December 2022 16 Supplement 1 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|